Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach
This paper examines effects of the German social health insurance system's reference drug program (RDP) for prescription drugs on ex‐factory prices. Moreover, we analyze whether manufacturers adapt prices of their products that are not subject to reference pricing as a consequence of changes in...
Gespeichert in:
| Veröffentlicht in: | Health economics 2009-04, Vol.18 (4), p.421-436 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 436 |
|---|---|
| container_issue | 4 |
| container_start_page | 421 |
| container_title | Health economics |
| container_volume | 18 |
| creator | Augurzky, Boris Göhlmann, Silja Greß, Stefan Wasem, Jürgen |
| description | This paper examines effects of the German social health insurance system's reference drug program (RDP) for prescription drugs on ex‐factory prices. Moreover, we analyze whether manufacturers adapt prices of their products that are not subject to reference pricing as a consequence of changes in reference prices of their products that are subject to reference pricing. We use econometric panel data methods based on a large panel data set of nearly all German prescription drugs on a monthly basis between October 1994 and July 2005. They provide information on ex‐factory prices, reference prices, manufacturers, type of prescription drug, and market entries and exits. Our results show that there is no full price adjustment: A 1%‐change in reference prices leads to a 0.3%‐change in market prices. Price adjustment, however, is fast – it mostly happens in the first month. Furthermore, the first introduction of a reference price reduces market prices of the affected products by approximately 7%. Finally, we observe a significant time effect that is positive in the market without reference prices and negative in the market with reference prices. Copyright © 2008 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/hec.1376 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67020021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67020021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5136-d452d91224856975b5f3a1c8bf66dbaaa9b1a9a8e0a161887a0099aeaf1f97a63</originalsourceid><addsrcrecordid>eNp1kVtv1TAMxysEYmMg8QlQxAPipSOXNml5Q0dnZ6AJJC7iMXJTd-3ojaRl67fH5RSQkHhwHCU_23_bUfRU8HPBuXxVozsXyuh70angeR4LnvL76z01cS4VP4kehXDDOf1x_TA6EZk2xsj0NOr3VYVuCmyo2FQjO6DvoGceK_TYO2Sln6_Z6IdrDx0beoZ3cQVuGvxCr43DX5Gjx-B8M04NEWtEeM2AjdBjy0qYgMFIKcDVj6MHFbQBn2z-LPpysf-8u4yvPhze7t5cxS4VSsdlksoyF1ImWapzkxZppUC4rKi0LgsAyAsBOWTIQWiRZQbW1gChElVuQKuz6MUxL5X9PmOYbNcEh21LkoY5WG24pMEJAp__A94Ms-9Jm5VKcq14tmZ7eYScH0Kg2VhqvQO_WMHtugBLC7DrAgh9d0Q9jvT2m7ttl7qdVuqHpU4yOhYy0pCTa8gSsnH1UthEaVtPHSV7tombiw7Lv1W39REQH4HbpsXlv6rs5X63qdv4Jkx494cH_40mokxqv74_WHnxKfl40Nzu1E8cTLbk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232063086</pqid></control><display><type>article</type><title>Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach</title><source>MEDLINE</source><source>RePEc</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><creator>Augurzky, Boris ; Göhlmann, Silja ; Greß, Stefan ; Wasem, Jürgen</creator><creatorcontrib>Augurzky, Boris ; Göhlmann, Silja ; Greß, Stefan ; Wasem, Jürgen</creatorcontrib><description>This paper examines effects of the German social health insurance system's reference drug program (RDP) for prescription drugs on ex‐factory prices. Moreover, we analyze whether manufacturers adapt prices of their products that are not subject to reference pricing as a consequence of changes in reference prices of their products that are subject to reference pricing. We use econometric panel data methods based on a large panel data set of nearly all German prescription drugs on a monthly basis between October 1994 and July 2005. They provide information on ex‐factory prices, reference prices, manufacturers, type of prescription drug, and market entries and exits. Our results show that there is no full price adjustment: A 1%‐change in reference prices leads to a 0.3%‐change in market prices. Price adjustment, however, is fast – it mostly happens in the first month. Furthermore, the first introduction of a reference price reduces market prices of the affected products by approximately 7%. Finally, we observe a significant time effect that is positive in the market without reference prices and negative in the market with reference prices. Copyright © 2008 John Wiley & Sons, Ltd.</description><identifier>ISSN: 1057-9230</identifier><identifier>EISSN: 1099-1050</identifier><identifier>DOI: 10.1002/hec.1376</identifier><identifier>PMID: 18677725</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Commerce - economics ; Cost Control ; Drug Costs - standards ; Drug Industry ; drug prices ; Econometrics ; Economic Competition ; Economics, Pharmaceutical - statistics & numerical data ; Germany ; Health care policy ; Health economics ; Health insurance ; Impact analysis ; Market prices ; Models, Econometric ; National Health Programs ; Prescription drugs ; Prescription Fees - standards ; Price elasticity ; reference drug program ; Studies ; temporal development</subject><ispartof>Health economics, 2009-04, Vol.18 (4), p.421-436</ispartof><rights>Copyright © 2008 John Wiley & Sons, Ltd.</rights><rights>(c) 2008 John Wiley & Sons, Ltd.</rights><rights>Copyright Wiley Periodicals Inc. Apr 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5136-d452d91224856975b5f3a1c8bf66dbaaa9b1a9a8e0a161887a0099aeaf1f97a63</citedby><cites>FETCH-LOGICAL-c5136-d452d91224856975b5f3a1c8bf66dbaaa9b1a9a8e0a161887a0099aeaf1f97a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhec.1376$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhec.1376$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,3994,27905,27906,30980,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18677725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/wlyhlthec/v_3a18_3ay_3a2009_3ai_3a4_3ap_3a421-436.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>Augurzky, Boris</creatorcontrib><creatorcontrib>Göhlmann, Silja</creatorcontrib><creatorcontrib>Greß, Stefan</creatorcontrib><creatorcontrib>Wasem, Jürgen</creatorcontrib><title>Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach</title><title>Health economics</title><addtitle>Health Econ</addtitle><description>This paper examines effects of the German social health insurance system's reference drug program (RDP) for prescription drugs on ex‐factory prices. Moreover, we analyze whether manufacturers adapt prices of their products that are not subject to reference pricing as a consequence of changes in reference prices of their products that are subject to reference pricing. We use econometric panel data methods based on a large panel data set of nearly all German prescription drugs on a monthly basis between October 1994 and July 2005. They provide information on ex‐factory prices, reference prices, manufacturers, type of prescription drug, and market entries and exits. Our results show that there is no full price adjustment: A 1%‐change in reference prices leads to a 0.3%‐change in market prices. Price adjustment, however, is fast – it mostly happens in the first month. Furthermore, the first introduction of a reference price reduces market prices of the affected products by approximately 7%. Finally, we observe a significant time effect that is positive in the market without reference prices and negative in the market with reference prices. Copyright © 2008 John Wiley & Sons, Ltd.</description><subject>Commerce - economics</subject><subject>Cost Control</subject><subject>Drug Costs - standards</subject><subject>Drug Industry</subject><subject>drug prices</subject><subject>Econometrics</subject><subject>Economic Competition</subject><subject>Economics, Pharmaceutical - statistics & numerical data</subject><subject>Germany</subject><subject>Health care policy</subject><subject>Health economics</subject><subject>Health insurance</subject><subject>Impact analysis</subject><subject>Market prices</subject><subject>Models, Econometric</subject><subject>National Health Programs</subject><subject>Prescription drugs</subject><subject>Prescription Fees - standards</subject><subject>Price elasticity</subject><subject>reference drug program</subject><subject>Studies</subject><subject>temporal development</subject><issn>1057-9230</issn><issn>1099-1050</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>X2L</sourceid><sourceid>7QJ</sourceid><recordid>eNp1kVtv1TAMxysEYmMg8QlQxAPipSOXNml5Q0dnZ6AJJC7iMXJTd-3ojaRl67fH5RSQkHhwHCU_23_bUfRU8HPBuXxVozsXyuh70angeR4LnvL76z01cS4VP4kehXDDOf1x_TA6EZk2xsj0NOr3VYVuCmyo2FQjO6DvoGceK_TYO2Sln6_Z6IdrDx0beoZ3cQVuGvxCr43DX5Gjx-B8M04NEWtEeM2AjdBjy0qYgMFIKcDVj6MHFbQBn2z-LPpysf-8u4yvPhze7t5cxS4VSsdlksoyF1ImWapzkxZppUC4rKi0LgsAyAsBOWTIQWiRZQbW1gChElVuQKuz6MUxL5X9PmOYbNcEh21LkoY5WG24pMEJAp__A94Ms-9Jm5VKcq14tmZ7eYScH0Kg2VhqvQO_WMHtugBLC7DrAgh9d0Q9jvT2m7ttl7qdVuqHpU4yOhYy0pCTa8gSsnH1UthEaVtPHSV7tombiw7Lv1W39REQH4HbpsXlv6rs5X63qdv4Jkx494cH_40mokxqv74_WHnxKfl40Nzu1E8cTLbk</recordid><startdate>200904</startdate><enddate>200904</enddate><creator>Augurzky, Boris</creator><creator>Göhlmann, Silja</creator><creator>Greß, Stefan</creator><creator>Wasem, Jürgen</creator><general>John Wiley & Sons, Ltd</general><general>Wiley Periodicals Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>200904</creationdate><title>Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach</title><author>Augurzky, Boris ; Göhlmann, Silja ; Greß, Stefan ; Wasem, Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5136-d452d91224856975b5f3a1c8bf66dbaaa9b1a9a8e0a161887a0099aeaf1f97a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Commerce - economics</topic><topic>Cost Control</topic><topic>Drug Costs - standards</topic><topic>Drug Industry</topic><topic>drug prices</topic><topic>Econometrics</topic><topic>Economic Competition</topic><topic>Economics, Pharmaceutical - statistics & numerical data</topic><topic>Germany</topic><topic>Health care policy</topic><topic>Health economics</topic><topic>Health insurance</topic><topic>Impact analysis</topic><topic>Market prices</topic><topic>Models, Econometric</topic><topic>National Health Programs</topic><topic>Prescription drugs</topic><topic>Prescription Fees - standards</topic><topic>Price elasticity</topic><topic>reference drug program</topic><topic>Studies</topic><topic>temporal development</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Augurzky, Boris</creatorcontrib><creatorcontrib>Göhlmann, Silja</creatorcontrib><creatorcontrib>Greß, Stefan</creatorcontrib><creatorcontrib>Wasem, Jürgen</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>Health economics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Augurzky, Boris</au><au>Göhlmann, Silja</au><au>Greß, Stefan</au><au>Wasem, Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach</atitle><jtitle>Health economics</jtitle><addtitle>Health Econ</addtitle><date>2009-04</date><risdate>2009</risdate><volume>18</volume><issue>4</issue><spage>421</spage><epage>436</epage><pages>421-436</pages><issn>1057-9230</issn><eissn>1099-1050</eissn><abstract>This paper examines effects of the German social health insurance system's reference drug program (RDP) for prescription drugs on ex‐factory prices. Moreover, we analyze whether manufacturers adapt prices of their products that are not subject to reference pricing as a consequence of changes in reference prices of their products that are subject to reference pricing. We use econometric panel data methods based on a large panel data set of nearly all German prescription drugs on a monthly basis between October 1994 and July 2005. They provide information on ex‐factory prices, reference prices, manufacturers, type of prescription drug, and market entries and exits. Our results show that there is no full price adjustment: A 1%‐change in reference prices leads to a 0.3%‐change in market prices. Price adjustment, however, is fast – it mostly happens in the first month. Furthermore, the first introduction of a reference price reduces market prices of the affected products by approximately 7%. Finally, we observe a significant time effect that is positive in the market without reference prices and negative in the market with reference prices. Copyright © 2008 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>18677725</pmid><doi>10.1002/hec.1376</doi><tpages>16</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1057-9230 |
| ispartof | Health economics, 2009-04, Vol.18 (4), p.421-436 |
| issn | 1057-9230 1099-1050 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67020021 |
| source | MEDLINE; RePEc; Wiley Online Library Journals Frontfile Complete; Applied Social Sciences Index & Abstracts (ASSIA) |
| subjects | Commerce - economics Cost Control Drug Costs - standards Drug Industry drug prices Econometrics Economic Competition Economics, Pharmaceutical - statistics & numerical data Germany Health care policy Health economics Health insurance Impact analysis Market prices Models, Econometric National Health Programs Prescription drugs Prescription Fees - standards Price elasticity reference drug program Studies temporal development |
| title | Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T14%3A16%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20the%20German%20reference%20drug%20program%20on%20ex-factory%20prices%20of%20prescription%20drugs:%20a%20panel%20data%20approach&rft.jtitle=Health%20economics&rft.au=Augurzky,%20Boris&rft.date=2009-04&rft.volume=18&rft.issue=4&rft.spage=421&rft.epage=436&rft.pages=421-436&rft.issn=1057-9230&rft.eissn=1099-1050&rft_id=info:doi/10.1002/hec.1376&rft_dat=%3Cproquest_cross%3E67020021%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232063086&rft_id=info:pmid/18677725&rfr_iscdi=true |